JP2025500288A5 - - Google Patents
Info
- Publication number
- JP2025500288A5 JP2025500288A5 JP2024536366A JP2024536366A JP2025500288A5 JP 2025500288 A5 JP2025500288 A5 JP 2025500288A5 JP 2024536366 A JP2024536366 A JP 2024536366A JP 2024536366 A JP2024536366 A JP 2024536366A JP 2025500288 A5 JP2025500288 A5 JP 2025500288A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence number
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21217465 | 2021-12-23 | ||
| EP21217465.0 | 2021-12-23 | ||
| PCT/EP2022/087829 WO2023118608A1 (en) | 2021-12-23 | 2022-12-23 | Discernible cell surface protein variants of cd45 for use in cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500288A JP2025500288A (ja) | 2025-01-09 |
| JP2025500288A5 true JP2025500288A5 (enExample) | 2026-01-06 |
Family
ID=79171049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536366A Pending JP2025500288A (ja) | 2021-12-23 | 2022-12-23 | 細胞療法に使用するためのｃｄ４５の識別可能な細胞表面タンパク質変異体 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4452417A1 (enExample) |
| JP (1) | JP2025500288A (enExample) |
| KR (1) | KR20240119146A (enExample) |
| CN (1) | CN118541158A (enExample) |
| AU (1) | AU2022422572A1 (enExample) |
| CA (1) | CA3240875A1 (enExample) |
| IL (1) | IL313785A (enExample) |
| MX (1) | MX2024007316A (enExample) |
| WO (1) | WO2023118608A1 (enExample) |
| ZA (1) | ZA202405124B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2026082736A1 (en) * | 2024-10-14 | 2026-04-23 | Cimeio Therapeutics Ag | Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170226209A1 (en) | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| WO2017155937A1 (en) | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| CN109641051A (zh) | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| WO2019084273A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| CN109991410B (zh) | 2017-12-29 | 2022-07-05 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
| WO2020018580A1 (en) | 2018-07-16 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell |
| EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| EP3877416A4 (en) | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF |
| WO2020092655A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| WO2020159656A1 (en) | 2019-02-01 | 2020-08-06 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| WO2020170254A1 (en) | 2019-02-21 | 2020-08-27 | Ramot At Tel-Aviv University Ltd. | Treatment of diseases with multimeric peptides |
-
2022
- 2022-12-23 AU AU2022422572A patent/AU2022422572A1/en active Pending
- 2022-12-23 WO PCT/EP2022/087829 patent/WO2023118608A1/en not_active Ceased
- 2022-12-23 CA CA3240875A patent/CA3240875A1/en active Pending
- 2022-12-23 IL IL313785A patent/IL313785A/en unknown
- 2022-12-23 JP JP2024536366A patent/JP2025500288A/ja active Pending
- 2022-12-23 EP EP22844175.4A patent/EP4452417A1/en active Pending
- 2022-12-23 KR KR1020247024216A patent/KR20240119146A/ko active Pending
- 2022-12-23 MX MX2024007316A patent/MX2024007316A/es unknown
- 2022-12-23 CN CN202280084880.8A patent/CN118541158A/zh active Pending
-
2024
- 2024-06-28 ZA ZA2024/05124A patent/ZA202405124B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6731403B2 (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| US20210024631A1 (en) | Bi-functional proteins and construction thereof | |
| TWI570135B (zh) | 高效、穩定且非免疫抑制之抗－ｃｄ４抗體 | |
| TW202112824A (zh) | 進一步與mhc分子結合的募集因子 | |
| CN107074951B (zh) | 拮抗性抗-ox40l抗体及其使用方法 | |
| CN114245807A (zh) | Flt3l-fc融合蛋白和使用方法 | |
| JP2019527543A5 (enExample) | ||
| JP2022521937A5 (enExample) | ||
| EP3833391A1 (en) | SIRP1alpha TARGETED CHIMERIC PROTEINS AND USES THEREOF | |
| KR102910874B1 (ko) | 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제 | |
| JP7507160B2 (ja) | ヒトｔｒｂｖ９に特異的に結合するモノクローナル抗体 | |
| JP2021529796A (ja) | 多特異性Ｗｎｔ代替分子及びその使用 | |
| JP2023123763A (ja) | Ｕｔｉ融合タンパク質 | |
| JP2025500288A5 (enExample) | ||
| JP2022532274A (ja) | ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体 | |
| JP2024546996A5 (enExample) | ||
| US11926676B2 (en) | Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such | |
| CN118451096A (zh) | 异二聚体fc细胞因子及其用途 | |
| JP2022500042A (ja) | 抗ｈｉｖ抗体１０−１０７４バリアント | |
| CN106459186A (zh) | 针对hiv‑1 v1v2 env区域的广谱中和性单克隆抗体 | |
| US20180111991A1 (en) | Modulators of activin and methods for modulating immune responses and t follicular helper cells | |
| JP2021527429A (ja) | 造血幹細胞を除去するための抗体薬物コンジュゲート | |
| JP7127859B2 (ja) | キメラタンパク質を用いたアレルギー疾患の治療 | |
| WO2022261846A1 (zh) | 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用 | |
| JP2023527918A5 (enExample) |